COPD market to reach $30.8 billion in 7MM by 2033: GlobalData
Express Pharma
OCTOBER 16, 2024
Other KOLs have communicated that Dupixent is to dominate the biologics market after receiving both EMA and FDA approval, filling a gap in the COPD market. The changes made by GOLD have communicated that ICS/LABA fixed-dose combinations should not be used, which has been reflected in the COPD report, highlighting a 1.4 billion by 2033.”
Let's personalize your content